| Literature DB >> 31819560 |
Kankan Gao1, Jie Fu1,2, Xiaoshan Guan1, Sufei Zhu1, Lanlan Zeng1, Xiaoming Xu1, Chien-Yi Chang3, Haiying Liu1.
Abstract
BACKGROUND: Neonatal sepsis (NS) is one of the leading causes of infant morbidity and mortality, but little is known about pathogen incidence and distribution in China.Entities:
Keywords: Escherichia coli; Klebsiella pneumoniae; antimicrobial resistance; group B Streptococcus; incidence; neonatal sepsis
Year: 2019 PMID: 31819560 PMCID: PMC6899077 DOI: 10.2147/IDR.S223597
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Distribution Of Organisms Causing Neonatal Sepsis
| Organism | Total (n/%) | Early Onset Sepsis (n/%) | Late Onset Sepsis (n/%) |
|---|---|---|---|
| 136/21.9 | 3/3.0 | 133/25.6 | |
| 136/21.9 | 20/20.0 | 116/22.3 | |
| 16/2.6 | 5/5.0 | 11/2.1 | |
| 12/1.9 | 1/1.0 | 11/2.1 | |
| 12/1.9 | 5/5.0 | 7/1.3 | |
| 7/1.1 | 1/1.0 | 6/1.2 | |
| 6/1.0 | 5/5.0 | 1/0.2 | |
| 6/1.0 | 0/0.0 | 6/1.2 | |
| 5/0.8 | 1/1.0 | 4/0.8 | |
| 5/0.8 | 0/0.0 | 5/1.0 | |
| Other Gram-negative bacteria | 30/4.8 | 8/8.0 | 27/5.2 |
| Group B | 82/13.2 | 30/30.0 | 52/10.0 |
| 42/6.8 | 2/2.0 | 40/7.7 | |
| Coagulase-negative | 25/4.0 | 5/5.0 | 20/3.8 |
| 19/3.1 | 2/2.0 | 17/3.3 | |
| 11/1.8 | 1/1.0 | 10/1.9 | |
| 8/1.3 | 3/3.0 | 5/1.0 | |
| 3/0.5 | 2/2.0 | 1/0.2 | |
| 3/0.5 | 1/1.0 | 2/0.4 | |
| 3/0.5 | 3/3.0 | 0/0.0 | |
| Other Gram-positive bacteria | 22/3.6 | 5/5.0 | 17/3.3 |
| 13/2.1 | 0/0.0 | 13/2.5 | |
| 8/1.3 | 1/1.0 | 7/1.3 | |
| 3/0.5 | 0/0.0 | 3/0.6 | |
| Other fungi | 7/1.1 | 1/1.0 | 6/1.2 |
Figure 1Proportions of term and preterm neonates, including very low birth weight (VLBW) and preterm low birth weight (PLBW), infected by different bacteria. CoNS, Coagulase-negative Staphylococcus; S. aureus, Staphylococcus aureus; GBS, Group B Streptococcus; K. pneumoniae, Klebsiella pneumoniae; E. coli, Escherichiacoli.
Figure 2Annual trends of the four predominant pathogens (Klebsiella pneumoniae, Escherichia coli, Group B Streptococcus (GBS), and Staphylococcus aureus) in (A) early-onset sepsis (EOS) and (B) late-onset sepsis (LOS) during 2012–2016.
Figure 3Incidence rate (per 1000 live births) of Klebsiella pneumoniae, Escherichia coli, Group B Streptococcus (GBS), and Staphylococcus aureus infections in (A) early-onset sepsis (EOS) and (B) late-onset sepsis (LOS).
Antibiotic Resistance Of Group B Streptococci (GBS) And Staphylococcus aureus
| GBS (n/N/%) | ||||||
|---|---|---|---|---|---|---|
| Penicillin | 0 | 80 | 0.0 | 37 | 42 | 88.1 |
| Ampicillin | 0 | 70 | 0.0 | – | – | – |
| Erythromycin | 61 | 78 | 70.9 | 14 | 42 | 33.3 |
| Tetracycline | 76 | 81 | 88.4 | 5 | 42 | 11.9 |
| Clindamycin | 55 | 81 | 64.0 | 14 | 42 | 33.3 |
| Nitrofurantoin | 0 | 69 | 0.0 | 1 | 42 | 2.4 |
| Ciprofloxacin | 10 | 71 | 11.6 | 0 | 42 | 0.0 |
| Moxifloxacin | 8 | 68 | 9.3 | 0 | 42 | 0.0 |
| Levofloxacin | 9 | 73 | 10.5 | 0 | 42 | 0.0 |
| Vancomycin | 0 | 80 | 0.0 | 0 | 42 | 0.0 |
| Tigecycline | 0 | 62 | 0.0 | 0 | 42 | 0.0 |
| Quinapril/duphuddin | 0 | 71 | 0.0 | 0 | 42 | 0.0 |
| Linezolid | 1 | 76 | 1.2 | 0 | 42 | 0.0 |
| Oxacillin | – | – | – | 8 | 42 | 19.0 |
| Cefazolin | – | – | – | 5 | 22 | 22.7 |
| Cefaclor | – | – | – | 5 | 22 | 22.7 |
| Cefuroxime | – | – | – | 5 | 22 | 22.7 |
| Cefoperazone | – | – | – | 5 | 22 | 22.7 |
| Ceftriaxone | – | – | – | 5 | 22 | 22.7 |
| Ceftazidime | – | – | – | 5 | 22 | 22.7 |
| Rifampicin | – | – | – | 0 | 42 | 0.0 |
| Trimethoprim/sulfamethoxazole | – | – | – | 2 | 42 | 4.8 |
| Gentamycin | – | – | – | 0 | 42 | 0.0 |
Notes: n, number of resistant isolates; N, number of tested.
Antibiotic Resistance Of Escherichia coli And Klebsiella Pneumoniae
| Ampicillin | 106 | 134 | 79.1 | 126 | 127 | 99.2 |
| Ampicillin/sulbactam | 37 | 131 | 27.6 | 70 | 122 | 55.1 |
| Piperacillin/tazobactam | 2 | 130 | 1.5 | 7 | 124 | 5.5 |
| Cefazolin | 57 | 128 | 42.5 | 82 | 121 | 64.6 |
| Ceftazidime | 15 | 134 | 11.2 | 41 | 126 | 32.3 |
| Ceftriaxone | 56 | 134 | 41.8 | 75 | 127 | 59.1 |
| Cefepime | 6 | 130 | 4.5 | 17 | 126 | 13.4 |
| Cefotetan | 3 | 131 | 2.2 | 8 | 122 | 6.3 |
| Imipenem | 1 | 134 | 0.7 | 8 | 127 | 6.3 |
| Ertapenem | 5 | 134 | 3.7 | 8 | 120 | 6.3 |
| Gentamycin | 42 | 134 | 31.3 | 26 | 127 | 20.5 |
| Amikacin | 1 | 134 | 0.7 | 2 | 127 | 1.6 |
| Tobramycin | 4 | 131 | 3.0 | 5 | 122 | 3.9 |
| Furadantin | 14 | 131 | 10.4 | 24 | 122 | 18.9 |
| Aztreonam | 26 | 131 | 19.4 | 45 | 123 | 35.4 |
| Ciprofloxacin | 44 | 134 | 32.8 | 9 | 127 | 7.1 |
| Levofloxacin | 29 | 131 | 21.6 | 13 | 123 | 10.2 |
| Trimethoprim/sulfamethoxazole | 68 | 131 | 50.7 | 46 | 122 | 36.2 |
Notes: n, number of resistant isolates; N, number tested.